UiPath Inc. (NYSE:PATH) Shares Acquired by Ieq Capital LLC

Ieq Capital LLC boosted its position in UiPath Inc. (NYSE:PATH) by 2.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,446,816 shares of the healthcare company’s stock after purchasing an additional 37,642 shares during the period. Ieq Capital LLC’s holdings in UiPath were worth $18,346,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Intech Investment Management LLC lifted its stake in UiPath by 3.1% during the fourth quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock valued at $356,000 after purchasing an additional 426 shares during the last quarter. Global Financial Private Client LLC lifted its position in shares of UiPath by 9.3% during the 1st quarter. Global Financial Private Client LLC now owns 6,471 shares of the healthcare company’s stock valued at $144,000 after acquiring an additional 551 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of UiPath by 1.7% during the 1st quarter. Principal Financial Group Inc. now owns 36,772 shares of the healthcare company’s stock worth $834,000 after acquiring an additional 622 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of UiPath by 40.2% in the 1st quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company’s stock worth $50,000 after acquiring an additional 632 shares during the last quarter. Finally, Lindbrook Capital LLC raised its position in shares of UiPath by 46.0% during the first quarter. Lindbrook Capital LLC now owns 2,027 shares of the healthcare company’s stock worth $46,000 after purchasing an additional 639 shares during the period. 62.50% of the stock is owned by institutional investors.

Insider Activity at UiPath

In related news, CFO Ashim Gupta sold 47,671 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $12.07, for a total transaction of $575,388.97. Following the transaction, the chief financial officer now directly owns 849,917 shares in the company, valued at $10,258,498.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.37% of the stock is owned by corporate insiders.

UiPath Stock Up 1.2 %

Shares of PATH stock opened at $12.45 on Friday. UiPath Inc. has a 12 month low of $10.37 and a 12 month high of $27.87. The firm has a market cap of $7.13 billion, a PE ratio of -77.81 and a beta of 0.87. The stock has a 50 day moving average of $12.12 and a 200-day moving average of $16.03.

UiPath (NYSE:PATH) last released its earnings results on Thursday, September 5th. The healthcare company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. The firm had revenue of $316.00 million during the quarter, compared to analysts’ expectations of $303.69 million. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.98%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.09) EPS. As a group, equities analysts predict that UiPath Inc. will post -0.23 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of UiPath in a research note on Friday, September 6th. Macquarie lowered shares of UiPath from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $29.00 to $12.00 in a research report on Monday, June 3rd. Mizuho lowered their target price on shares of UiPath from $25.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, May 30th. Truist Financial reaffirmed a “hold” rating and issued a $14.00 price target (down previously from $32.00) on shares of UiPath in a research report on Thursday, May 30th. Finally, BMO Capital Markets increased their price objective on UiPath from $14.00 to $15.00 and gave the company a “market perform” rating in a report on Friday, September 6th. Sixteen research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $17.71.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.